Loading viewer...
earnings
Format: PDF earnings
Halozyme Therapeutics reported third quarter 2023 financial and operating results, highlighting progress with its ENHANZE drug delivery technology platform and auto-injector business. The company announced a $250 million accelerated share repurchase program and discussed forward-looking expectations for revenue growth, profitability, and strategic partnerships driving ENHANZE adoption across therapeutic applications.
conference
20 Pages
earnings
15 Pages
Air Liquide
Zebra Technologies Q1 2023 Earnings Results
earningsearnings
24 Pages
Zebra Technologies
Bajaj Finance Q3 FY19 Investor Presentation 2019
earningsearnings
51 Pages
Bajaj Finance Limited